Keywords
Graft Survival
Metabolic dysfunction-associated steatotic liver disease (MASLD)
Non-alcoholic fatty liver disease (NAFLD)
Lean MASLD
How to Cite
Abstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent hepatic disease with metabolic dysfunction-associated steatohepatitis (MASH) as its severe necro-inflammatory subtype. At present, it is the second leading cause of liver transplant. A systematic literature review (SLR) was conducted to assess the effect of lean vs non-lean BMI on clinical outcomes after transplant in MASLD patients.
Methods: A systematic search of PubMed, Cochrane Library, and Google Scholar databases was executed. Review Manager 5.4.1 was used for statistical analyses. A random-effect model was used with the results reported as Odds Ratio (OR) and 95% confidence interval (CI). A narrative approach was used where it was not feasible to conduct a meta-analysis.
Results: Eleven observational studies were included in the SLR. Pooled results from three studies showed no significant difference in mortality between lean and non-lean patients at 1 year (OR= 0.78, p= 0.76), 2 years (OR= 0.83, p= 0.24), and 5 years (OR= 1.07, p= 0.51) post-transplant. There was also no significant relation of lean and non-lean BMI in graft survival, observed over 30 days (OR= 1.34, p= 0.27), 1 year (OR= 0.75, p= 0.25), 2 years (OR= 1.20, p= 0.45), and 5 years (OR= 1.07, p= 0.60) post-transplant. Qualitative analysis suggested morbid obesity is linked with higher waitlist dropout in MASH patients.
Conclusion: The qualitative analysis of eight studies indicates a trend towards poorer outcomes in the non-lean group. There is a need for further investigations to comprehensively examine the factors influencing the relationship between BMI and post-transplant outcomes.
References
1. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018: 908 [PMID: 29967350, https://doi.org/10.1038/s41591-018-0104-9]
2. Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen AA. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022: 851 [PMID: 35798021, https://doi.org/10.1016/S2468-1253(22)00165-0]
3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016: 73 [PMID: 26707365, https://doi.org/10.1002/hep.28431]
4. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015: 367 [PMID: 25865049, https://doi.org/10.1053/j.gastro.2015.04.005]
5. Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwalder M, El-Serag HB, Finn RS, Friedman SL. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023: 487 [PMID: 36932227, https://doi.org/10.1038/s41575-023-00754-7]
6. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023: 1335 [PMID: 36626630, https://doi.org/10.1097/HEP.0000000000000004]
7. Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2016 Annual Data Report: Liver. Am J Transplant. 2018: 172 [PMID: 29292603, https://doi.org/10.1111/ajt.14559]
8. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A, Global Nonalcoholic Steatohepatitis C. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2019: 748 [PMID: 29908364, https://doi.org/10.1016/j.cgh.2018.05.057]
9. Barone M, Viggiani MT, Losurdo G, Principi M, Leandro G, Di Leo A. Systematic review with meta-analysis: post-operative complications and mortality risk in liver transplant candidates with obesity. Aliment Pharmacol Ther. 2017: 236 [PMID: 28488418, https://doi.org/10.1111/apt.14139]
10. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014: 394 [PMID: 24076414, https://doi.org/10.1016/j.cgh.2013.09.023]
11. Zhou GP, Jiang YZ, Sun LY, Zhu ZJ. Clinical evidence of outcomes following liver transplantation in patients with nonalcoholic steatohepatitis: An updated meta-analysis and systematic review. Int J Surg. 2022: 106752 [PMID: 35803515, https://doi.org/10.1016/j.ijsu.2022.106752]
12. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catala-Lopez F, Gotzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015: 777 [PMID: 26030634, https://doi.org/10.7326/M14-2385]
13. Kuchay MS, Martinez-Montoro JI, Choudhary NS, Fernandez-Garcia JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines. 2021: [PMID: 34680463, https://doi.org/10.3390/biomedicines9101346]
14. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019: ED000142 [PMID: 31643080, https://doi.org/10.1002/14651858.ED000142]
15. Qazi-Arisar FA, Uchila R, Chen C, Yang C, Chen SY, Karnam RS, Azhie A, Xu W, Galvin Z, Selzner N, Lilly L, Bhat M. Divergent trajectories of lean vs obese non-alcoholic steatohepatitis patients from listing to post-transplant: A retrospective cohort study. World J Gastroenterol. 2022: 3218 [PMID: 36051335, https://doi.org/10.3748/wjg.v28.i26.3218]
16. Leonard J, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant. 2008: 667 [PMID: 18294163, https://doi.org/10.1111/j.1600-6143.2007.02100.x]
17. Conzen KD, Vachharajani N, Collins KM, Anderson CD, Lin Y, Wellen JR, Shenoy S, Lowell JA, Doyle MB, Chapman WC. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis. HPB (Oxford). 2015: 251 [PMID: 25322849, https://doi.org/10.1111/hpb.12340]
18. Eshraghian A, Nikeghbalian S, Geramizadeh B, Kazemi K, Shamsaeefar A, Malek-Hosseini SA. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid. Clin Res Hepatol Gastroenterol. 2020: 572 [PMID: 31611031, https://doi.org/10.1016/j.clinre.2019.09.002]
19. Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, Feurstein B, Popp W, Karam V, Muiesan P, O'Grady J, Jamieson N, Wigmore SJ, Pirenne J, Malek-Hosseini SA, Hidalgo E, Tokat Y, Paul A, Pratschke J, Bartels M, Trunecka P, Settmacher U, Pinzani M, Duvoux C, Newsome PN, Schneeberger S, European L, Intestine Transplant A. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019: 313 [PMID: 31071367, https://doi.org/10.1016/j.jhep.2019.04.011]
20. Kardashian AA, Dodge JL, Roberts J, Brandman D. Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. Liver Int. 2018: 553 [PMID: 28727287, https://doi.org/10.1111/liv.13523]
21. Satapathy SK, Jiang Y, Agbim U, Wu C, Bernstein DE, Teperman LW, Kedia SK, Aithal GP, Bhamidimarri KR, Duseja A, Maiwall R, Maliakkal B, Jalal P, Patel K, Puri P, Ravinuthala R, Wong VW, Abdelmalek MF, Ahmed A, Thuluvath PJ, Singal AK, Global NC. Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox. Liver Transpl. 2020: 68 [PMID: 31665561, https://doi.org/10.1002/lt.25672]
22. Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathe Z, Gerken G, Paul A, Canbay A, Treckmann JW. Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion. 2012: 107 [PMID: 22846254, https://doi.org/10.1159/000339344]
23. Kennedy C, Redden D, Gray S, Eckhoff D, Massoud O, McGuire B, Alkurdi B, Bloomer J, DuBay DA. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford). 2012: 625 [PMID: 22882200, https://doi.org/10.1111/j.1477-2574.2012.00497.x]
24. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009: 782 [PMID: 19344467, https://doi.org/10.1111/j.1600-6143.2009.02590.x]
25. Eshraghian A, Nikeghbalian S, Kazemi K, Shamsaeefar A, Geramizadeh B, Malek-Hosseini SA. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis. HPB (Oxford). 2020: 521 [PMID: 31431413, https://doi.org/10.1016/j.hpb.2019.07.015]
26. Moctezuma-Velazquez C, Marquez-Guillen E, Torre A. Obesity in the Liver Transplant Setting. Nutrients. 2019: [PMID: 31652761, https://doi.org/10.3390/nu11112552]
27. Beckmann S, Drent G, Ruppar T, Nikolic N, De Geest S. Body Weight Parameters are Related to Morbidity and Mortality After Liver Transplantation: A Systematic Review and Meta-analysis. Transplantation. 2019: 2287 [PMID: 31283679, https://doi.org/10.1097/TP.0000000000002811]
28. Orci LA, Majno PE, Berney T, Morel P, Mentha G, Toso C. The impact of wait list body mass index changes on the outcome after liver transplantation. Transpl Int. 2013: 170 [PMID: 23199077, https://doi.org/10.1111/tri.12017]
29. Rustgi VK, Marino G, Rustgi S, Halpern MT, Johnson LB, Tolleris C, Taddei TH. Impact of body mass index on graft failure and overall survival following liver transplant. Clin Transplant. 2004: 634 [PMID: 15516235, https://doi.org/10.1111/j.1399-0012.2004.00141.x]
30. Lee DU, Bahadur A, Ponder R, Lee KJ, Fan GH, Chou H, Lominadze Z. The causes of death in patients with nonalcoholic steatohepatitis following liver transplantation stratified using pre-liver transplant BMI. Hepatol Int. 2023: 1393 [PMID: 37160862, https://doi.org/10.1007/s12072-023-10529-6]
31. Jih J, Mukherjea A, Vittinghoff E, Nguyen TT, Tsoh JY, Fukuoka Y, Bender MS, Tseng W, Kanaya AM. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med. 2014: 1 [PMID: 24736092, https://doi.org/10.1016/j.ypmed.2014.04.010]
32. Coelho JC, Parolin MB, Matias JE, Jorge FM, Canan Junior LW. [Cause of late death in liver transplant recipients]. Rev Assoc Med Bras (1992). 2003: 177 [PMID: 12886396, https://doi.org/10.1590/s0104-42302003000200037]
33. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010: 431 [PMID: 20373454, https://doi.org/10.1002/lt.22004]
34. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol. 2010: 613 [PMID: 20040915, https://doi.org/10.1038/ajg.2009.717]
35. Burra P, Germani G, Gnoato F, Lazzaro S, Russo FP, Cillo U, Senzolo M. Adherence in liver transplant recipients. Liver Transpl. 2011: 760 [PMID: 21384527, https://doi.org/10.1002/lt.22294]
36. Grat K, Pacho R, Grat M, Krawczyk M, Zieniewicz K, Rowinski O. Impact of Body Composition on the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation. J Clin Med. 2019: [PMID: 31614892, https://doi.org/10.3390/jcm8101672]
37. El-Domiaty N, Saliba F, Karam V, Sobesky R, Ibrahim W, Vibert E, Pittau G, Amer K, Saeed MA, Shawky JA, Cherqui D, Adam R, Samuel D. Impact of body mass index on hepatocellular carcinoma recurrence after liver transplantation through long-term follow-up. Hepatobiliary Surg Nutr. 2021: 598 [PMID: 34760964, https://doi.org/10.21037/hbsn.2020.04.01]
38. Siegel AB, Lim EA, Wang S, Brubaker W, Rodriguez RD, Goyal A, Jacobson JS, Hershman DL, Verna EC, Zaretsky J, Halazun K, Dove L, Brown RS, Jr., Neugut AI, Kato T, Remotti H, Coppleson YJ, Emond JC. Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation. 2012: 539 [PMID: 22864187, https://doi.org/10.1097/TP.0b013e31825c58ea]
39. Zhang Z, Zhang L, Jiang W, Du T, Yuan G. Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients. Cardiovasc Diabetol. 2022: 210 [PMID: 36242001, https://doi.org/10.1186/s12933-022-01648-9]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 ASIDE Gastroenterology